About Opexa Therapeutics
Opexa Therapeutics is a company based in The Woodlands (United States) founded in 2004 was acquired by Acer Therapeutics in July 2017. Opexa Therapeutics has raised $5.84 million across 3 funding rounds from investors including Acer Therapeutics. The company has 9 employees as of December 31, 2016. Opexa Therapeutics offers products and services including Tcelna and OPX-212. Opexa Therapeutics operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, Poseida Therapeutics and Juno Therapeutics, among others.
- Headquarter The Woodlands, United States
- Employees 9 as on 31 Dec, 2016
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Opexa Therapeutics, Inc.
-
Annual Revenue
$2.91 M (USD)14as on Dec 31, 2016
-
Net Profit
-$7.98 M (USD)34as on Dec 31, 2016
-
EBITDA
-$7.75 M (USD)34as on Dec 31, 2016
-
Total Equity Funding
$5.84 M (USD)
in 3 rounds
-
Latest Funding Round
$650 K (USD), Series A
Feb 15, 2013
- Investors
-
Employee Count
9
as on Dec 31, 2016
-
Acquired by
Acer Therapeutics
(Jul 03, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Opexa Therapeutics
Opexa Therapeutics offers a comprehensive portfolio of products and services, including Tcelna and OPX-212.
Personalized T-cell therapy for multiple sclerosis treatment
Autologous T-cell therapy for neuromyelitis optica
Funding Insights of Opexa Therapeutics
Opexa Therapeutics has successfully raised a total of $5.84M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $650 thousand completed in February 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Opexa Therapeutics
Opexa Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Acer Therapeutics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Treatments for ultra-rare diseases like vEDS and MSUD are developed.
|
Locked | Locked | Locked |
Investor details for Opexa Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Opexa Therapeutics
Investment portfolio details for Opexa Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Opexa Therapeutics
Detailed financials for Opexa Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Opexa Therapeutics Comparisons
Peer comparison for Opexa Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Opexa Therapeutics
Opexa Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, Poseida Therapeutics and Juno Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
Detailed competitors of Opexa Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Opexa Therapeutics
Complete news archive for Opexa Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Opexa Therapeutics
Opexa Therapeutics was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Opexa Therapeutics is headquartered in The Woodlands, United States. It is registered at The Woodlands, Texas, United States.
Opexa Therapeutics is a funded company, having raised a total of $5.84M across 3 funding rounds to date.
As of Dec 31, 2016, the latest employee count at Opexa Therapeutics is 9.
Annual revenue of Opexa Therapeutics is $2.91M as on Dec 31, 2016.
Opexa Therapeutics was established in 2004 through the merger of PharmaFrontiers and Opexa Pharmaceuticals. Patient-specific immunotherapies are developed by the company for multiple sclerosis treatment within the biotechnology sector. The leading candidate, Tcelna, is designed for Secondary Progressive Multiple Sclerosis. Operations are conducted from The Woodlands, United States, focusing on autoimmune disease applications.
Opexa Therapeutics's top competitors include ADMA Biologics, Juno Therapeutics and Lyell Immunopharma.
Opexa Therapeutics offers Tcelna and OPX-212.
Opexa Therapeutics has 1 investor. Key investors include Acer Therapeutics.